PMNOC Proceedings.

On January 29, 2026, the Minister of Health announced Anie Perrault, former Vice-Chairperson, as Chairperson of the Patented Medicine Prices Review Board (PMPRB) until August 9, 2028.

In June 2019, the Minister of Health tabled a report, A Prescription for Canada: Achieving Pharmacare for All, recommending that Canada implement universal, single-payer, public pharmacare (Pharmacare).

On October 19, 2023, the Ontario Ministry of Health proposed regulatory amendments under the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA) to align...

We previously reported amendments to Part 1.1 of the Medical Devices Regulations that created a permanent regulatory framework for expediting access to COVID-19 medical devices.

It is possible that this date will be further extended.

On June 28th, 2021, the Government of Canada announced that it is again, offering Indigenous Intellectual Property Program (IIPP) grants.

After almost two years of suspense for pharma industry stakeholders, the Government of Canada will proceed with the implementation of some

On July 17, the Canadian Patent Office launched MyCIPO Patents. The highly anticipated new database and filing system allows for immediate application number confirmation when filing online...

On August 8, 2025, the Federal Court of Appeal (FCA) determined that the Minister of Health's decision to list Canadian Patent No. 2,970,315 on the Patent Register eight days...

Traditional cultural expressions and knowledge are invaluable assets to Indigenous communities, yet they often do not align with the protections offered by Western IP systems.

On April 19th, 2021, the Canadian Federal government tabled its first budget since the last federal election.

The World Health Organization (WHO) and the Medicines Patent Pool (MPP) secured a license from the Spanish National Research Council (CSIC; Consejo Superior de Investigaciones Científicas) ...

ENTRESTO (sacubitril-valsartan)

Over ten years have passed since the Federal Court of Appeal (FCA) flagged the patentability of methods of medical treatment as being worthy of full consideration by the Supreme Court of Canada. This issue has finally come before the Court.

The Board decision was quashed, and the case was sent back to the Board for redetermination.

There are multiple ongoing class actions in Canada against pharmaceutical companies related to Opioid Use Disorder (OUD) and its effects. While these proceedings are all currently in their early stages...

Taro Pharmaceuticals v Biogen and Acorda Therapeutics.

Canada's Anti-Spam Legislation (CASL) is enforced by three federal agencies, the Canadian Radio-television and Telecommunications Commission (CRTC)...

The Industrial Design Office has announced that it is changing its practice with respect to industrial designs applied to buildings or structures.